Beatriz Caiuby Labate Clancy Cavnar Editors Ayahuasca Healing and Science Ayahuasca Healing and Science Beatriz Caiuby Labate • Clancy Cavnar Editors

Total Page:16

File Type:pdf, Size:1020Kb

Load more

Beatriz Caiuby Labate Clancy Cavnar Editors Ayahuasca Healing and Science Ayahuasca Healing and Science Beatriz Caiuby Labate • Clancy Cavnar Editors Ayahuasca Healing and Science Editors Beatriz Caiuby Labate Clancy Cavnar Chacruna Institute for Psychedelic Plant Chacruna Institute for Psychedelic Plant Medicines Medicines San Francisco, CA, USA San Francisco, CA, USA ISBN 978-3-030-55687-7 ISBN 978-3-030-55688-4 (eBook) https://doi.org/10.1007/978-3-030-55688-4 © Springer Nature Switzerland AG 2021 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifcally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microflms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specifc statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affliations. This Springer imprint is published by the registered company Springer Nature Switzerland AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland Preface The book you are now reading, Ayahuasca Healing and Science, is both timely and far-reaching. It covers the range of aspects of ayahuasca’s legendary healing capac- ity, looking at the ways psychological healing is realized from consumption of a drink. Teasing apart the factors that constitute “healing” is the job of science. Here, we give deep consideration to the micro as well as the macro; from asking what the molecules in ayahuasca are and how do they change the way we think and feel, to looking at the protocols and reasons for ayahuasca-based treatment of multiple mental health disorders. This book presents research projects where scientists use neuroimaging tech- niques to explore the neural correlates underlying ayahuasca’s healing of problem- atic patterns of thought and are able to measure its ability to enhance meta-cognition and address broad patterns of dysfunction. It is not just the emotions and neurons that are affected by treatment with ayahuasca; we also take a look at the way thoughts themselves are transformed. Cognitive behavioral therapy is successful because it confronts the distorted thoughts that lead to anxiety and depression; research is revealing that ayahuasca also interferes with problematic cognitions. Its effects reveal a complex interplay between the chemical world of molecules, the world of emotions, and the world of thought, visions, and insights. The use of this powerful agent in psychotherapy must take into account its sometimes- overwhelming and unsettling effect, especially on survivors of trauma who might not be emotionally prepared for the diffcult visions and painful insights ayahuasca can provide. These considerations are important in respect to the patients who are in most need of the sublime power of ayahuasca. The problems of treating delicate emotional conditions with the sometimes-caustic cleanser that is ayahuasca are addressed herein. The use of ayahuasca as an antidepressant, an anti-addictive agent, and as a treat- ment for PTSD, eating disorders, and childhood trauma points to the wide range of applications for this magical drink. Has there ever been such a multifaceted sub- stance with such a helpful profle? Among the issues covered in this volume, we can read about ayahuasca resolving distressing mental health symptoms by weakening egocentrism, enhancing cognitive adaptability and the capacity to regulate emotions, v vi Preface improving mindfulness, and enhancing connection to nature. This book addresses ayahuasca’s healing potential for addictions in particular, with three chapters focus- ing on this topic. We conclude the volume with an interview with a Shipibo healer on his perspectives on ayahuasca healing, a return to the indigenous view from whence all ayahuasca cures originate. This book adds to the growing collection of data on this hallucinogen-religious sacrament-medicinal plant-magical potion, and we hope it encourages others to take seriously the rumors and legends circulating about the power of ayahuasca, not as a naïve believer in myths, but as a logical and discerning student of science who demands proof for such remarkable claims. The body of knowledge on this drink is expanding and we are beginning to see connections that were not apparent before, as anthropology, psychology, and the medical and biological sciences contribute their viewpoints. Why has ayahuasca’s use expanded so fast globally? What does it offer in com- parison to other medicines? Why is this so popular now? Did ayahuasca come to heal us? Is it here by pure chance? Can it reveal a deeper structure to reality? For now, we may rely on the researchers and scientists who provide proof that, at the very least, ayahuasca is a potent medicine with broad applications for what ails humanity. San Francisco, CA, USA Clancy Cavnar Beatriz Caiuby Labate Foreword: Will the Queen Save Us? It is of no small signifcance that Ayahuasca Healing and Science, edited by the indefatigable scholars Beatriz Labate and Clancy Cavnar, will be published in 2020: the year of the pandemic, when predatory capitalism, White male supremacy, police brutality, and other aspects of patriarchy fnally meet a crisis of their own making that is big enough to drown all of it. As the process unravels archaic forms of social organization, the attrition leaves behind a trail of traumas; emotional scars that reverberate psychic distress, pain, and despair. We live through an epidemic of depression and suicide. People of all walks of life need healing, and this is why this book is so timely. Ayahuasca is a sacred Amerindian medicine whose use is spreading internation- ally across cultures and beliefs. In the past decade, the therapeutic use of ayahuasca received scientifc support from the experts listed below, including the hardcore pioneer Jordi Riba. The plurality of views was ensured by the choice of a very diverse set of authors from a wide range of felds and countries, from neuroscience to anthropology, from psychiatry to clinical psychology, from biochemistry to holis- tic psychotherapy. While the solid therapeutic effects of ayahuasca are well represented in the book, such as in the work of Brazilian researchers on the potent antidepressant effects of ayahuasca, there is a clear effort in several chapters to chart the risks and constraints of ayahuasca use. There is also a proactive determination to map the several blind spots and unknowns of this feld, which include molecular, physiological, psychiat- ric, and cross-cultural gaps. In the coming years, many of the important questions raised in this book shall be answered by qualitative and quantitative research. It will be performed by the growing cohort of scientists dedicated to the study of this won- derful medicine, many of them authors of chapters in this book. Ayahuasca has an exceedingly special place in the pharmacopeia of the reborn (and increasingly free) use of psychedelics for healing in Western medicine. Its head-to-head comparison with psilocybin and ketamine has yet to be performed, but it is clear that ayahuasca is a major contestant for the most potent psychedelic anti- depressant. The main chemical components present in the brew, harmine and N,N- dimethyltryptamine (N,N-DMT), as well as the related compound 5-MeO DMT, vii viii Foreword: Will the Queen Save Us? present in the secretion of the toad Bufo alvarius and in the yopo plant snuff, have been demonstrated to induce several cellular changes related to the formation of new synapses and even new neurons entirely, as shown by the research groups of Stevens Rehen (Dakic et al., 2016; Dakic et al., 2017), Richardson Leão (Lima da Cruz et al., 2018), and David Olson (Ly et al. 2018). Congruent results were recently seen for d-LSD by a consortium of my laboratory with those of Stevens Rehen, Draulio de Araujo, Luis Fernando Tófoli, and Daniel Martins-de-Souza, with sup- port from the Beckley Foundation (Cini et al., 2019). The powerful synergistic effects of mixing two or more molecules able to pro- mote synaptogenetic and neurogenetic effects, as is the case of ayahuasca, likely leads to a potent “entourage effect” that may prove as dramatic as that originally proposed by the great Raphael Mechoulam and colleagues concerning the coopera- tive effects of the multiple cannabinoids, which may increase clinical effcacy (Ben- Shabat et al., 1998). It is important to note, however, that the fact that ayahuasca represents concrete hope for those in need of major neural reorganization is not only related to its bio- logical effects. The interaction of psychedelic substances with set and setting repre- sents a wide range of therapeutic possibilities. In this regard, ayahuasca also occupies a distinguished and strategic place due to the richness and sophistication of the Amerindian and syncretic rituals that make ayahuasca a true queen among the sacred organisms required to mitigate the ongoing mental health crisis that charac- terizes the twenty-frst century. Sidarta Ribeiro, Ph.D. References Ben-Shabat, S., Fride, E., Sheskin, T., Tamiri, T., Rhee, M. H., Vogel, Z., Bisogno, T., De Petrocellis, L., Di Marzo, V., & Mechoulam, R.
Recommended publications
  • Plant-Based Medicines for Anxiety Disorders, Part 2: a Review of Clinical Studies with Supporting Preclinical Evidence

    Plant-Based Medicines for Anxiety Disorders, Part 2: a Review of Clinical Studies with Supporting Preclinical Evidence

    CNS Drugs 2013; 24 (5) Review Article Running Header: Plant-Based Anxiolytic Psychopharmacology Plant-Based Medicines for Anxiety Disorders, Part 2: A Review of Clinical Studies with Supporting Preclinical Evidence Jerome Sarris,1,2 Erica McIntyre3 and David A. Camfield2 1 Department of Psychiatry, Faculty of Medicine, University of Melbourne, Richmond, VIC, Australia 2 The Centre for Human Psychopharmacology, Swinburne University of Technology, Melbourne, VIC, Australia 3 School of Psychology, Charles Sturt University, Wagga Wagga, NSW, Australia Correspondence: Jerome Sarris, Department of Psychiatry and The Melbourne Clinic, University of Melbourne, 2 Salisbury Street, Richmond, VIC 3121, Australia. Email: [email protected], Acknowledgements Dr Jerome Sarris is funded by an Australian National Health & Medical Research Council fellowship (NHMRC funding ID 628875), in a strategic partnership with The University of Melbourne, The Centre for Human Psychopharmacology at the Swinburne University of Technology. Jerome Sarris, Erica McIntyre and David A. Camfield have no conflicts of interest that are directly relevant to the content of this article. 1 Abstract Research in the area of herbal psychopharmacology has revealed a variety of promising medicines that may provide benefit in the treatment of general anxiety and specific anxiety disorders. However, a comprehensive review of plant-based anxiolytics has been absent to date. Thus, our aim was to provide a comprehensive narrative review of plant-based medicines that have clinical and/or preclinical evidence of anxiolytic activity. We present the article in two parts. In part one, we reviewed herbal medicines for which only preclinical investigations for anxiolytic activity have been performed. In this current article (part two), we review herbal medicines for which there have been both preclinical and clinical investigations for anxiolytic activity.
  • Medicinal Cannabis and Psychoactive Plants for Mental Health and Addiction

    Medicinal Cannabis and Psychoactive Plants for Mental Health and Addiction

    Medicinal cannabis and psychoactive plants for mental health and addiction University of Melbourne Research Forum Friday 28 June 2019 Overview Since the establishment of legal access pathways in November 2016 over 8000 Australian patients have gained access to cannabis-based medicines for the treatment of a wide range of indications, most commonly chronic pain and cancer. However, there is now a growing interest in the use of medicinal cannabis for the treatment of psychiatric and substance use disorders. At the same time there is a resurgence of interest in a range of other psychoactive plants and related compounds for this same group of indications. New research programs have been established at eminent institutions such as Johns Hopkins, Imperial College London and NYU with researchers involved reporting remarkable early results. Both psilocybin and MDMA, for example, are now entering Phase 3 trials and have recently been granted breakthrough therapy status by the FDA on the basis of initial evidence indicating they may demonstrate a substantial improvement over existing therapies for treatment-resistant depression and PTSD respectively. To explore the latest research in this field, as well as regulatory frameworks being implemented internationally to enable medicinal access, the School of Social and Political Science and Department of Psychiatry at the University of Melbourne, in partnership with the Penington Institute, are holding a one-day research forum on this topic in June. The forum is for invited researchers, policy makers
  • Journal Pre-Proof

    Journal Pre-Proof

    Journal Pre-proof Ayahuasca Use and Reported Effects on Depression and Anxiety Symptoms: An International Cross-Sectional Study of 11,912 Consumers Jerome Sarris , Daniel Perkins , Lachlan Cribb , Violeta Schubert , Emerita Opaleye , Jose´ Carlos Bouso , Milan Scheidegger , Helena Aicher , Hana Simonova , Miroslav Horak , Nicole Leite Galvao-Coelho˜ , David Castle , Lu´ıs Fernando Tofoli´ PII: S2666-9153(21)00025-1 DOI: https://doi.org/10.1016/j.jadr.2021.100098 Reference: JADR 100098 To appear in: Journal of Affective Disorders Reports Received date: 6 January 2021 Revised date: 20 January 2021 Accepted date: 28 January 2021 Please cite this article as: Jerome Sarris , Daniel Perkins , Lachlan Cribb , Violeta Schubert , Emerita Opaleye , Jose´ Carlos Bouso , Milan Scheidegger , Helena Aicher , Hana Simonova , Miroslav Horak , Nicole Leite Galvao-Coelho˜ , David Castle , Lu´ıs Fernando Tofoli´ , Ayahuasca Use and Reported Effects on Depression and Anxiety Symptoms: An International Cross- Sectional Study of 11,912 Consumers, Journal of Affective Disorders Reports (2021), doi: https://doi.org/10.1016/j.jadr.2021.100098 This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
  • Ayahuasca Use and Reported Effects on Depression and Anxiety Symptoms

    Ayahuasca Use and Reported Effects on Depression and Anxiety Symptoms

    Journal of Affective Disorders Reports 4 (2021) 100098 Contents lists available at ScienceDirect Journal of Affective Disorders Reports journal homepage: www.elsevier.com/locate/jadr Research Paper Ayahuasca use and reported effects on depression and anxiety symptoms: An international cross-sectional study of 11,912 consumers Jerome Sarris a,b,∗, Daniel Perkins c, Lachlan Cribb b, Violeta Schubert c, Emerita Opaleye d, José Carlos Bouso e, Milan Scheidegger f, Helena Aicher f, Hana Simonova g, Miroslav Horák h, Nicole Leite Galvão-Coelho a,i, David Castle j,k, Luís Fernando Tófoli d a NICM Health Research Institute, Western Sydney University, Westmead, Australia b Professorial Unit, The Melbourne Clinic, Department of Psychiatry, University of Melbourne, Melbourne, Australia c School of Social and Political Science, University of Melbourne d Department of Psychobiology, Universidade Federal de São Paulo, São Paulo, Brazil e Interdisciplinary Cooperation for Ayahuasca Research and Outreach (ICARO), University of Campinas, Campinas, Brazil f Department of Psychiatry, Psychotherapy and Psychosomatics, Psychedelic Research & Therapy Development, University of Zurich, Switzerland g Private Psychology Practice h Mendel University Brno, Zemedelska, Czech Republic i Postgraduate Program in Psychobiology and Department of Physiology and Behavior, Federal University of Rio Grande do Norte, Natal-RN, Brazil j St Vincent’s Hospital, Department of Psychiatry, University of Melbourne, Melbourne, Australia k Centre for Complex Interventions, Centre for Addictions and Mental Health, University of Toronto, Canada a r t i c l e i n f o a b s t r a c t Keywords: Background: Ayahuasca is a psychoactive Amazonian brew which has emerging data indicating that it has an- Ayahuasca tidepressant and anxiolytic properties.
  • Download the Abstracts and Speaker Profiles (PDF, 3202.8

    SPEAKER PROFILES AND PRESENTATION ABSTRACTS NICM HEALTH RESEARCH INSTITUTE SYMPOSIUM 12 AUGUST 2021 MEDICINAL CANNABIS: RESEARCH, REGULATION AND EDUCATION Health Research Institute NICM HEALTH RESEARCH INSTITUTE – MEDICINAL CANNABIS RESEARCH SYMPOSIUM AUGUST 2021 1 PROFESSOR DENNIS CHANG WELCOME ADDRESS Director, NICM Health Research Institute, Western Sydney University Dennis Chang is the Director of NICM Health Research Institute and a Professor of Pharmacology. He is also the lead of NICM Health Research Institute’s Healthy Hearts Research Program. His research interests include clinical and pharmacological studies of herbal medicine and other complementary medicine interventions at the Institute. As the leading investigator of several significant clinical trials, Professor Chang’s research projects have centred around evaluating herbal medicine, yoga and tai chi for the treatment of dementia, mild cognitive impairment, coronary heart disease, metabolic syndrome and type 2 diabetes. He has also linkedin.com/in/prof-dennis-chang been involved in preclinical research to evaluate molecular mechanisms and synergistic interactions of active components of herbal medicine. Professor Chang’s research has been published in a broad range of high-quality peer-reviewed journals such as British Journal of Pharmacology, Clinical Pharmacology and Therapeutics, Drug, and Journal of Translational Medicine. His research has been supported by various competitive funding agencies, governments and industry totalling $7M. Prior to joining NICM Health Research Institute, Professor Chang served a number of academic leadership roles within Western Sydney University including Research Director of School of Science and Health, and Associate Head of School of Biomedical and Health Science. He initially trained in medicine and received postgraduate training in pharmacology.
  • Medicinal Psychedelics for Mental Health

    Medicinal Psychedelics for Mental Health

    998785ANP ANZJP PerspectivesPerkins et al. Viewpoint Australian & New Zealand Journal of Psychiatry 1 –7 Medicinal psychedelics for mental https://doi.org/10.1177/0004867421998785DOI: 10.1177/0004867421998785 © The Royal Australian and health and addiction: Advancing New Zealand College of Psychiatrists 2021 Article reuse guidelines: research of an emerging paradigm sagepub.com/journals-permissions journals.sagepub.com/home/anp Daniel Perkins1 , Jerome Sarris2,3 , Susan Rossell4,5 , Yvonne Bonomo6,7, David Forbes8, Christopher Davey8, Daniel Hoyer9,10, Colleen Loo11,12 , Greg Murray4, Sean Hood13 , Violeta Schubert1, Nicole Leite Galvão-Coelho14, Meaghen O’Donnell8, Olivia Carter15, Paul Liknaitzky16,17 , Martin Williams18, Dan Siskind19,20 , David Penington21, Michael Berk8,22,23,24 and David Castle25 Abstract The medical use of psychedelic substances (e.g. psilocybin, ayahuasca, lysergic acid diethylamide and 3,4-methylenedioxymethamphetamine) is attracting renewed interest, driven by a pressing need for research and development of novel therapies for psychiatric disorders, as well as promising results of contemporary studies. In this Viewpoint, we reflect upon the ‘Clinical Memorandum on Psychedelics’ recently released by the Royal Australian and New Zealand College of Psychiatrists and note subsequent developments including the application for down- scheduling of psilocybin and 3,4-methylenedioxymethamphetamine presently being considered by the Therapeutic Goods Administration and approvals for access via the Special Access Scheme.
  • Nutraceuticals for Major Depressive Disorder-More Is Not Merrier: an 8

    Nutraceuticals for Major Depressive Disorder-More Is Not Merrier: an 8

    Accepted Manuscript Nutraceuticals for Major Depressive Disorder- More is Not Merrier: an 8-week double-blind, randomized, controlled trial Jerome Sarris PhDMHSc , Gerard J Byrne MBBSPhD , Con Stough PhD , Chad Bousman PhDMPH , David Mischoulon MDPhD , Jenifer Murphy BPsych (hons)PhD , Patricia MacDonald BPsych (Hons) , Laura Adams BPsychMCouns , Sonia Nazareth MPsych , Georgina Oliver MSc , Lachlan Cribb BSci (Hons) , Karen Savage BPsych (Hons) , Ranjit Menon MD , Suneel Chamoli MD , Michael Berk MDPhD , Chee Ng MBBSMD PII: S0165-0327(18)31411-3 DOI: https://doi.org/10.1016/j.jad.2018.11.092 Reference: JAD 10310 To appear in: Journal of Affective Disorders Received date: 29 June 2018 Revised date: 18 October 2018 Accepted date: 12 November 2018 Please cite this article as: Jerome Sarris PhDMHSc , Gerard J Byrne MBBSPhD , Con Stough PhD , Chad Bousman PhDMPH , David Mischoulon MDPhD , Jenifer Murphy BPsych (hons)PhD , Patricia MacDonald BPsych (Hons) , Laura Adams BPsychMCouns , Sonia Nazareth MPsych , Georgina Oliver MSc , Lachlan Cribb BSci (Hons) , Karen Savage BPsych (Hons) , Ranjit Menon MD , Suneel Chamoli MD , Michael Berk MDPhD , Chee Ng MBBSMD , Nutraceu- ticals for Major Depressive Disorder- More is Not Merrier: an 8-week double-blind, randomized, controlled trial, Journal of Affective Disorders (2018), doi: https://doi.org/10.1016/j.jad.2018.11.092 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.